Compare Eli Lilly And Co (LLY) vs OneSpan Inc (OSPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs OneSpan Inc — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while OneSpan Inc trades at $18.22 (market cap $662.97M). The key difference: Eli Lilly And Co is far larger — about 1568.7× OneSpan Inc's market cap, and OneSpan Inc pays the higher dividend (2.89%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and OneSpan Inc for 18 Days on average.
| LLY | OSPN | |
|---|---|---|
Market Cap | $1.04T | $662.97M |
Volume | 3,064,878 | 616,882 |
Sector | Health | Technology |
52-Week High | $1.28K | $18.42 |
52-Week Low | $799.57 | $10.15 |
Typical Hold Time | 93 Days | 18 Days |
Enterprise Value | $1.09T | $632.05M |
Dividend Yield | 0.59% | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company's weight-loss drug portfolio continues to drive exceptional performance, with Q2 2026 EPS of $8.38 beating expectations by 31%. Technical indicators show bullish moving averages while fundamentals reveal impressive 83.4% gross margins and 102.44% ROE. Recent clinical trial successes for next-generation obesity treatments position Lilly for continued market leadership.
LLY presents a compelling growth story with dominant positioning in the expanding obesity/diabetes market, though elevated valuations (P/E 39.26) and regulatory risks require monitoring. Analyst consensus remains strongly bullish with $1,350 price target representing 15% upside. The primary investment thesis centers on pipeline execution and market expansion opportunities, balanced against competitive pressures and valuation concerns.
OneSpan (OSPN) trades at $18.01, up 1.75% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with a 27.76% net margin and consistent earnings beats, though 2026 projections show slight margin compression. Recent product innovation with DigipassONE and institutional interest from Deutsche Bank highlight growth potential amid competitive pressures.
Outlook remains positive with 67% analyst buy ratings and attractive valuation at 10.16 P/E, but investors face risks from subscription transition execution and market volatility. The stock's current technical positioning near key resistance at $19 requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
